CN111479808A - 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用 - Google Patents

嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN111479808A
CN111479808A CN201880074739.3A CN201880074739A CN111479808A CN 111479808 A CN111479808 A CN 111479808A CN 201880074739 A CN201880074739 A CN 201880074739A CN 111479808 A CN111479808 A CN 111479808A
Authority
CN
China
Prior art keywords
compound
alkyl
room temperature
added
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880074739.3A
Other languages
English (en)
Other versions
CN111479808B (zh
Inventor
罗云富
雷茂义
栗俊苗
徐雨
魏冉
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Zhikang Hongyi Biotechnology Co ltd
Original Assignee
Shijiazhuang Sagacity New Drug Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Sagacity New Drug Development Co Ltd filed Critical Shijiazhuang Sagacity New Drug Development Co Ltd
Publication of CN111479808A publication Critical patent/CN111479808A/zh
Application granted granted Critical
Publication of CN111479808B publication Critical patent/CN111479808B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

公开了一系列嘧啶磺酰胺类化合物，及其在制备ETA受体拮抗剂相关疾病的药物中的应用。具体公开了式(I)所示衍生化合物、其互变异构体或其药学上可接受的组合物。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201880074739.3A 2017-11-21 2018-11-19 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用 Active CN111479808B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017111681113 2017-11-21
CN201711168111 2017-11-21
PCT/CN2018/116196 WO2019101039A1 (zh) 2017-11-21 2018-11-19 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN111479808A true CN111479808A (zh) 2020-07-31
CN111479808B CN111479808B (zh) 2023-02-24

Family

ID=66630436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880074739.3A Active CN111479808B (zh) 2017-11-21 2018-11-19 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用

Country Status (19)

Country Link
US (1) US11319305B2 (zh)
EP (1) EP3719013B1 (zh)
JP (1) JP7245832B2 (zh)
CN (1) CN111479808B (zh)
AU (1) AU2018372752B2 (zh)
BR (1) BR112020010149A8 (zh)
CA (1) CA3083019A1 (zh)
DK (1) DK3719013T3 (zh)
ES (1) ES2936864T3 (zh)
FI (1) FI3719013T3 (zh)
HR (1) HRP20230318T1 (zh)
HU (1) HUE061515T2 (zh)
IL (1) IL274773B2 (zh)
LT (1) LT3719013T (zh)
PL (1) PL3719013T3 (zh)
PT (1) PT3719013T (zh)
RS (1) RS64040B1 (zh)
SI (1) SI3719013T1 (zh)
WO (1) WO2019101039A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
BR112021023328A8 (pt) * 2019-05-22 2023-04-25 Shijiazhuang Sagacity New Drug Dev Co Ltd Forma de cristal de composto de pirimidina sulfonamida e método de preparação para a mesma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072597A1 (en) * 1999-07-29 2001-01-31 Pfizer Limited Pyrazoles and their use as endothelin antagonists
EP1160248A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
CN1524079A (zh) * 2000-12-18 2004-08-25 ������˹ҩƷ��˾ 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1711248A (zh) * 2002-12-02 2005-12-21 埃科特莱茵药品有限公司 嘧啶－磺酰胺及其作为内皮素受体拮抗剂的应用
CN101056872A (zh) * 2004-11-11 2007-10-17 埃科特莱茵药品有限公司 用于治疗心血管疾病作为内皮素受体拮抗剂的磺酰二胺

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3490959B2 (ja) 2000-07-11 2004-01-26 三洋電機株式会社 受光素子及び受光モジュール

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072597A1 (en) * 1999-07-29 2001-01-31 Pfizer Limited Pyrazoles and their use as endothelin antagonists
JP2001064262A (ja) * 1999-07-29 2001-03-13 Pfizer Inc ピラゾール類
EP1160248A1 (en) * 2000-05-31 2001-12-05 Pfizer Inc. N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
JP2002020385A (ja) * 2000-05-31 2002-01-23 Pfizer Inc 新規なイソオキサゾール−スルホンアミドエンドセリンアンタゴニスト
CN1524079A (zh) * 2000-12-18 2004-08-25 ������˹ҩƷ��˾ 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1711248A (zh) * 2002-12-02 2005-12-21 埃科特莱茵药品有限公司 嘧啶－磺酰胺及其作为内皮素受体拮抗剂的应用
CN101056872A (zh) * 2004-11-11 2007-10-17 埃科特莱茵药品有限公司 用于治疗心血管疾病作为内皮素受体拮抗剂的磺酰二胺

Also Published As

Publication number Publication date
HUE061515T2 (hu) 2023-07-28
HRP20230318T1 (hr) 2023-05-12
EP3719013A1 (en) 2020-10-07
PT3719013T (pt) 2023-02-01
BR112020010149A8 (pt) 2023-01-17
IL274773B2 (en) 2023-08-01
CN111479808B (zh) 2023-02-24
EP3719013B1 (en) 2023-01-04
IL274773B1 (en) 2023-04-01
WO2019101039A1 (zh) 2019-05-31
JP2021504330A (ja) 2021-02-15
RU2020119900A3 (zh) 2021-12-23
EP3719013A4 (en) 2021-04-21
US20200283425A1 (en) 2020-09-10
LT3719013T (lt) 2023-05-10
AU2018372752B2 (en) 2023-02-02
RU2020119900A (ru) 2021-12-23
US11319305B2 (en) 2022-05-03
DK3719013T3 (da) 2023-04-03
FI3719013T3 (fi) 2023-04-03
ES2936864T3 (es) 2023-03-22
PL3719013T3 (pl) 2023-05-08
CA3083019A1 (en) 2019-05-31
BR112020010149A2 (pt) 2020-11-10
IL274773A (en) 2020-07-30
RS64040B1 (sr) 2023-04-28
JP7245832B2 (ja) 2023-03-24
SI3719013T1 (sl) 2023-05-31
AU2018372752A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
KR102089234B1 (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
BR112020001124A2 (pt) composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto ou do sal farmaceuticamente aceitável do mesmo e método para tratamento de câncer
EP3333157B1 (en) Vinyl compounds as fgfr and vegfr inhibitors
US10513514B2 (en) Piperidine compounds as PCSK9 inhibitors
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
TWI788424B (zh) 受體抑制劑的并環類衍生物
JP7123956B2 (ja) スピロ化合物およびその使用
CN110023286B (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN111479808A (zh) 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用
KR20230159543A (ko) 6-카바메이트로 치환된 헤테로방향족 고리 유도체
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
EP3620454B1 (en) Carboxylic acid derivative as at2r receptor antagonist
CN109071469B (zh) 三环类化合物及其应用
EP3473628B1 (en) Dihydropyrazole azepine compound serving as akt inhibitor
CN110741003B (zh) 作为gls1抑制剂的化合物
RU2773844C2 (ru) Производное пиримидинсульфамида и способ его получения, и медицинское применение
RU2773844C9 (ru) Производное пиримидинсульфамида и способ его получения, и медицинское применение
WO2022253333A1 (zh) 酰胺类化合物及其应用
CN109563093A (zh) 作为crth2抑制剂的三并环类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220629

Address after: 214000 room 315, No. 88, Meishan Meiliang Road, Binhu District, Wuxi City, Jiangsu Province

Applicant after: Wuxi Zhikang Hongyi Biotechnology Co.,Ltd.

Address before: 050035 16th floor, innovation building, No. 315, Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei

Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant